Cryptococcal antigen (CrAg) precedes fulminant cryptococcal meningitis, and preemptive treatment of those CrAg positive before development of meningitis is life-saving. The World Health Organization recommends screening and preemptive treatment for those with a CD4<100 cells/µL who are initiating ART. However, the proportion of patients presenting with fulminant cryptococcal meningitis is increasingly ART-experienced. It is not clear if there is a role for CrAg screening among ART-experienced persons with virologic failure. We evaluated CrAg prevalence among ART-experienced persons with suspected virologic failure in Uganda, and present 6-month survival and incidence of meningitis among CrAg-positive persons.
We retrospectively performed CrAg testing on plasma samples of adults with virologic failure (HIV viral load >1000 copies/mL) between September 2017 and January 2018. For those CrAg-positive, ART history, incidence of cryptococcal meningitis, and 6-month survival were obtained from retrospective medical chart review.
We tested 1186 plasma samples of patients with viral loads >1000 copies/mL and found 35 CrAg-positive (prevalence of 2.95%). Of the 35 CrAg-positive persons, median ART duration was 42 months (IQR 14 to 78 months). We obtained 6-month outcome data on 21 CrAg-positive patients. Of these, 15 were alive, and 6 were dead. Five survivors were known to have received fluconazole. Two patients developed meningitis and survived with treatment. Thus, meningitis-free survival at 6-months was 13/21 (62%). Median viral load for CrAg negative was 11,650 copies/mL (IQR: 3,465 to 54,950), whereas median viral load for CrAg positives was 53,700 copies/mL (IQR: 17,513 to 163,500), (p<0.0001). Overall, 91% (32/35) of CrAg-positive persons had viral loads >5000 copies/mL compared with 64% (735/1149) of CrAg-negative (Odds Ratio = 6.0; 95%CI, 1.8 to 19.7, P=0.001). CrAg prevalence increased among higher viral loads with 4.2% (32/768) CrAg-positivity among those with >5000 copies/mL and 0.9% (5/553) CrAg-positivity among those with <5000 copies/mL
CrAg prevalence was ~3% among ART-experienced persons with virologic failure, and median viral load was higher in CrAg positives compared to CrAg negatives. Meningitis-free survival was 62% at 6-months. Further studies to evaluate the potential benefit of CrAg screening in the ART-experienced population are warranted.